New trick to tame prostate radiation: shrink the gland first!
NCT ID NCT07251829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a procedure called prostate artery embolization (PAE) can reduce urinary side effects from radiotherapy in men with prostate cancer. Participants have large prostates or existing urinary symptoms. They will receive PAE before starting radiation, and researchers will track changes in urinary function and side effects over six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prostatic Artery Embolization (a procedure to shrink the prostate by blocking its blood supply)
What this could lead to
If it works, this could offer a way to reduce urinary problems from radiotherapy, making treatment easier to tolerate for men with larger prostates.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. The procedure itself carries risks like pain or bleeding, and it's not yet clear if it will meaningfully reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.